

# Seth Baum

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7756715/seth-baum-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

1,939  
citations

19  
h-index

43  
g-index

60  
ext. papers

2,801  
ext. citations

7.4  
avg, IF

4.78  
L-index

#	Paper	IF	Citations
47	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 244-255	59.2	265
46	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 850-61	18.1	215
45	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 662-680	15.1	215
44	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 2012-2024	4.0	193
43	Fatty acids in cardiovascular health and disease: a comprehensive update. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 216-34	4.9	164
42	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1780-1788	27.4	155
41	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <i>Circulation: Cardiovascular Genetics</i> , <b>2016</b> , 9, 240-9		126
40	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , <b>2020</b> , 41, 3936-3945	9.5	83
39	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 243-254	3.3	52
38	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , <b>2020</b> , 1, 100009	1.9	43
37	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 1223-9	4.9	41
36	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , <b>2017</b> , 267, 19-26	3.1	36
35	Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005404	5.8	29
34	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , <b>2017</b> , 135, 2204-2206	16.7	28
33	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 264-275	18.1	28
32	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 1234-1243.e5	4.9	25
31	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. <i>The Lancet Digital Health</i> , <b>2019</b> , 1, e393-e402	14.4	24

30	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	23
29	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1926-1942	15.1	19
28	MR imaging in the definition of coronary artery anomalies. <i>Journal of Computer Assisted Tomography</i> , <b>1990</b> , 14, 171-4	2.2	15
27	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 940-948	3	13
26	Statins and diabetes. <i>Cardiology Clinics</i> , <b>2015</b> , 33, 233-43	2.5	12
25	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2017</b> , 19, 58	2.1	12
24	Statins and Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2016</b> , 45, 87-100	5.5	10
23	Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 901-909.e3	4.9	10
22	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 829	3.3	9
21	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	8
20	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , <b>2021</b> , 17, 155-174	1.3	7
19	PCSK9 inhibitor valuation: A science-based review of the two recent models. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 544-550	3.3	6
18	A Survey of Internists and Cardiologists: Are Discoveries in Fatty Acids Truly being translated into Clinical Practice?. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2013</b> , 88, 3-4	2.8	5
17	Fatty Acids and Their Derivatives in Cardiovascular Disease: Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids and Their Byproducts, the Eicosanoids and Docosanoids. <i>Current Cardiovascular Risk Reports</i> , <b>2012</b> , 6, 146-154	0.9	5
16	Acute reversible diffuse conduction system disease due to Lyme disease. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1990</b> , 13, 1367-70	1.6	5
15	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. <i>Postgraduate Medicine</i> , <b>2016</b> , 128 Suppl 1, 31-9	3.7	4
14	ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 454-5	3	4
13	CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2534	15.1	2

12	The American Society for Preventive Cardiology: Our 30-year legacy. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 627-630,	3.3	2
11	Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 434-7	4.9	2
10	EPA and DHA: distinct yet essential n-3 fatty acids. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 477; author reply 477-9	4.9	2
9	Pitfalls of population-based preventive medicine. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2201-2	27.4	2
8	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , <b>2021</b> , 8, 100278	1.9	2
7	Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. <i>American Journal of Preventive Cardiology</i> , <b>2021</b> , 8, 100477	1.9	2
6	Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified. <i>Therapeutics and Clinical Risk Management</i> , <b>2019</b> , 15, 1325-1332	2.9	2
5	Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. <i>Reviews in Cardiovascular Medicine</i> , <b>2016</b> , 17, 16-27	3.9	2
4	A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes. <i>Cardiovascular Endocrinology</i> , <b>2017</b> , 6, 39-43		1
3	The American Society for Preventive Cardiology. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 709	3.3	1
2	From the "Ivory Tower" to the trenches: A practical approach to the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines. <i>Journal of Clinical Lipidology</i> , <b>2014</b> , 8, 231-3	4.9	1
1	Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey. <i>Clinical Lipidology</i> , <b>2015</b> , 10, 431-448		